Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
ID: 357747Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357747

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-019.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), is offering a funding opportunity titled "Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers." This initiative aims to support research proposals that develop and test multi-level interventions to improve the quality of transitional care and enhance engagement for over 500,000 U.S. cancer survivors transitioning from pediatric to adult healthcare systems. The program emphasizes addressing health disparities and requires applications to demonstrate scalability and sustainability of proposed interventions, fostering effective communication between patients and providers. The total funding available is approximately $10 million, with a maximum annual budget cap of $499,000 per project over a five-year period. Interested applicants must submit their proposals by October 18, 2025, with projects expected to commence in March 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-019.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-25-019-Full-Announcement.html
    RFA-CA-25-019.html
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), is issuing a funding opportunity aimed at addressing healthcare transition barriers for survivors of childhood and adolescent cancers. This initiative, titled "Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers," invites research proposals focused on developing and testing multi-level interventions to improve transitional care quality and survivor engagement within adult health systems. Specifically, the program seeks to enhance long-term outcomes for over 500,000 U.S. cancer survivors who are at risk for chronic health complications post-treatment. The anticipated total funding is $10 million, allowing approximately 12 awarded applications, with a maximum annual budget cap of $499,000 per project over a 5-year period. Emphasis is placed on interventions that address disparities in health outcomes, utilizing a multidisciplinary approach to evaluate various strategies and their efficacy. Applications must detail scalability and sustainability while fostering communication between patients and providers throughout the transition. The deadline for applications is set for October 18, 2025, with an earliest start date for successful projects planned for March 2026.
    Similar Opportunities
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity aimed at improving care and outcomes for cancer survivors from sexual and gender minority (SGM) populations. This initiative seeks proposals for observational and interventional studies that assess barriers to quality cancer treatment and follow-up care for SGM individuals, utilizing interoperable sexual orientation and gender identity (SOGI) data collection methods. The funding is crucial for addressing healthcare disparities faced by SGM cancer survivors and aims to foster culturally sensitive care and effective interventions. Applications are due starting January 5, 2024, with funding available for up to five years, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting research projects that enhance cancer communication strategies. The initiative focuses on three key areas: the application of new cancer communication surveillance methods, the development of rapid pilot interventions, and the creation of multilevel communication models that emphasize bidirectional influences in cancer prevention and control. This funding, available through R21 exploratory/developmental grants, provides up to $275,000 for a maximum of two years, with applications due starting January 16, 2025. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Transition Career Development Award (K22), a federal grant aimed at supporting researchers transitioning from mentored, non-independent positions to their first independent tenure-track faculty roles in cancer research. This grant provides funding for up to three years, covering both salary and research development expenses, with the goal of enhancing the applicant's potential to secure independent NIH grants and fostering a diverse pool of capable scientists in the biomedical field. Eligible applicants include various institutions and organizations, particularly those serving underrepresented groups, and must adhere to detailed application guidelines. Interested parties can find more information and apply before the closing date of November 12, 2025, by visiting the NIH grants website or contacting NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.